Loading clinical trials...

A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE1

A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus

A Phase 1 Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Moderate or Severe Systemic Lupus Erythematosus

NCT06373991•EdiGene Inc.

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to test ATHENA CAR-T injection in adults with moderate to severe Systemic Lupus Erythematosus. The main question it aims to answer is: • To evaluate the safety and tolerability of ATHENA CAR-T. After screening, participants will be subjected to lymphodepletion regimen. After recovery, participants will be injected with ATHENA CAR-T injection and followed up to 24 months.

Detailed Description

This study is a single center, one-arm, open label, phase I study aimed at evaluate the safety and effectiveness of ATHENA CAR-T treating moderate to severe SLE patients. A traditional "3+3" design is used with two doses. DLT is monitored. Safety and effectiveness are followed up until 24 months post infusion of ATHENA CAR-T. Besides safety monitoring, efficacy is evaluated via SLEDAI-2000, BILAG-2004, PGA.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or Female, between 18 and 56 years old;
•diagnosed with SLE according to 2019 EULAR/ACR SLE classifications;
•anti-Nuclear Antigen Ab positive (titer NLT 1:80) and/or dsDNA ab positive and/or Anti-Sm ab positive at screening;
•at screening, SLEDAI-2000 scoring NLT 8 points, if low complement scoring and/or anti-dsDNA ab scoring is available, the SLEDAI-2000 scoring except low complement and anti-dsDNA ab should be NLT 6 points;
•should be subjected to at least 6 months of standard treatment for SLE, and disease active at least two months before screening;
•good organ functions;
•trial participants whose partner is fertile agree to use effective contraceptives til 24 months post transfusion, fertile female participants should have negative urine/blood pregnancy test results (participants who were sterilized or menopause for MT 12 months is not considered fertile);
•voluntary participates this trial and can comprehend and sign ICF.

Exclusion Criteria

•Had or has active malignancy;
•had been subjected to treatment by CD19 targeted therapy or CAR-T therapy or any gene therapy;
•within 8 weeks before screening, had CNS disease caused by SLE or non-SLE diseases;
•within 8 weeks before screening, had lupus crisis;
•has following kidney diseases: within 8 weeks before randomization, had SLE with serious kidney involvement or need treatment using medications prohibited by protocol to treat active nephritis, or need hemodialysis or need treatment by prednisone MT 100mg/d for longer than 14d or equivalent therapy;
•had serious allergy to any lymphodepletion medication or ingredients of ATHENA CAR-T;
•has uncontrolled fungi, bacterial or viral infection or other infections investigator deemed not suitable to participate in the study;
•combined with other autoimmune disease that needs treatment;
•pregnant or lactating women;
•has other factors that deemed not suitable by investigator.

Locations (1)

The First Affiliated Hospital of Henan University of Science and Technology

Luoyang, Henan, China

Key Dates

Start Date

July 24, 2024

Primary Completion Date

April 30, 2027

Completion Date

April 30, 2027

Last Updated

June 17, 2024

Enrollment

ESTIMATED participants

Conditions

Lupus Erythematosus, Systemic

Interventions

ATHENA CAR-T

BIOLOGICAL

Fludarabine

DRUG

Cyclophosphamide

DRUG

Contacts

Chao Liu

CONTACT

(86)-10-80733899 cliu@edigene.com

Yiding Zhao, PhD

CONTACT

(86)-10-80733899 ydzhao@edigene.com

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

NCT07015983

Lupus Erythematosus, SystemicLupus Nephritis

View study

RECRUITINGPHASE3

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496

Lupus Erythematosus, Systemic

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 17, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus

Inclusion Criteria

Exclusion Criteria

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus

Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases